A Phase 1/2 Open-Label, Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Gastroesophageal Cancer: Master (KE

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Junaid Arshad
Sponsor
Merck Sharp & Dohme Corp.
Unit
Cancer Center Division